Loading...
XHKG
8158
Market cap17mUSD
Jun 13, Last price  
0.45HKD
1D
8.54%
Jan 2017
-99.13%
IPO
-96.29%
Name

China Regenerative Medicine International Ltd

Chart & Performance

D1W1MN
P/E
7.71
P/S
1.51
EPS
0.06
Div Yield, %
—
Shrs. gr., 5y
28.18%
Rev. gr., 5y
13.57%
Revenues
91m
+30.41%
42,427,00064,952,00088,760,00024,448,00030,0002,621,000128,0001,377,000510,0002,817,00027,751,000356,987,000755,520,00072,952,00047,971,000185,339,000282,897,000231,612,00069,487,00090,617,000
Net income
18m
P
1,777,000-374,000-3,457,00021,092,000-64,569,000-42,061,000-57,109,000-61,320,000-263,442,000-250,098,000-190,902,000-184,502,000-237,738,000-1,193,501,000-447,743,000-289,708,00051,827,0004,555,000-107,699,00017,752,000
CFO
0k
-100.00%
4,710,000-1,523,000-8,472,000-18,847,000-9,444,000-102,726,00022,251,000-90,007,000-126,033,000-218,325,000-99,117,000-460,893,000-217,755,00018,751,000-23,332,000-397,741,000-3,022,000-17,654,0006,338,0000
Dividend
Sep 24, 20020 HKD/sh

Profile

China Regenerative Medicine International Limited, an investment holding company, produces and sells healthcare products and services. The company offers health management services, such as assessment of health situation, treatment for detox, balance of inner body, nourishing organs, and enhancement of immune system; and beauty services comprising non-surgical medical aesthetic services, basic skincare, solutions for youthful skin, hair revitalizing, lines firming, partial remodelling, and intimate repairing services. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Tsim Sha Tsui, Hong Kong.
URL
http://www.crmi.hk/
IPO date
Jul 18, 2001
Employees
29
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑042016‑04
Income
Revenues
90,617
30.41%
69,487
-70.00%
231,612
-18.13%
Cost of revenue
84,481
95,599
219,806
Unusual Expense (Income)
NOPBT
6,136
(26,112)
11,806
NOPBT Margin
6.77%
5.10%
Operating Taxes
3,712
Tax Rate
31.44%
NOPAT
6,136
(26,112)
8,094
Net income
17,752
-116.48%
(107,699)
-2,464.41%
4,555
-91.21%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
8,217
24,024
58,330
Long-term debt
50,061
41,150
37,280
Deferred revenue
(147)
Other long-term liabilities
6,170
147
Net debt
824
61,840
93,761
Cash flow
Cash from operating activities
6,338
(17,654)
CAPEX
(274)
(2,591)
Cash from investing activities
(262)
(2,590)
Cash from financing activities
(7,364)
7,322
FCF
83,240
64,024
(28,409)
Balance
Cash
57,454
3,334
1,849
Long term investments
Excess cash
52,923
Stockholders' equity
25,197
(2,820,076)
(2,716,141)
Invested Capital
59,860
2,882,060
2,866,501
ROIC
0.42%
0.54%
ROCE
7.21%
7.84%
EV
Common stock shares outstanding
304,252
286,409
285,429
Price
0.27
-51.82%
0.55
-49.54%
1.09
-61.07%
Market cap
80,627
-48.82%
157,525
-49.37%
311,118
-61.07%
EV
81,451
219,365
788,335
EBITDA
6,136
(14,795)
11,977
EV/EBITDA
13.27
65.82
Interest
979
781
Interest/NOPBT
6.62%